Latest GeneDx News & Updates

See the latest news and media coverage for GeneDx. We track all announcements, press releases, and industry mentions in real time, all in one place.

GeneDx

Rare disease genetic testing and genomic diagnostics company

genedx.com

Headquarters: Stamford, United States
Company type: Public company
Number of employees: 1,200–5,000
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about GeneDx

In short: GeneDx returned to profitability in Q2 2026, expanded pediatric genomic testing access, and secured a $100 million term loan facility.

Company announcements

August 19 GeneDx

GeneDx launches guided ordering experience in its Provider Portal

Easy Order simplifies ExomeDx with CMA submissions by streamlining workflows and reducing administrative steps for pediatricians.

August 3 GeneDx

GeneDx reports Q2 2026 revenue of $114.4 million

Revenue grew 11% year-over-year, with exome and genome revenue up 17% to $100.3 million. Adjusted net income was $0.4 million.

July 17 GeneDx

GeneDx advocates for expanded genomic testing coverage

The company lobbied for the GACHA bill, shared SAVES Kids study results, and discussed AI at a health policy salon.

June 16 GeneDx

GeneDx names Mark Gardner President

He joins from Quest Diagnostics to lead commercial and operations teams, focusing on execution and efficient scaling.

Media coverage

September 8 Investing.com

GeneDx at Wells Fargo healthcare conference: growth and collections in focus By Investing.com

The company’s gross profit margin of 69% in the last twelve months aligns closely with management’s stated 70% target, while its market capitalization stands at...

August 15 Simply Wall St

GeneDx Holdings (WGS), Why Is This Fresh Development Drawing Attention? - Simply Wall St News

GeneDx Holdings (WGS) has caught investor attention after launching a new online pathway for exome testing that lets U.S. families start clinician-guided genetic tests for...

August 7 Daily Political

GeneDx (NASDAQ:WGS) Price Target Raised to $90.00 - Daily Political

GeneDx (NASDAQ:WGS – Free Report) had its price target lifted by Canaccord Genuity Group from $75.00 to $90.00 in a report published on Tuesday, Marketbeat...

August 5 Seeking Alpha

Mid-cap Sell streak: Stocks trapped longest in bearish Quant ratings

Discover 2026’s weakest mid-cap stocks: 10 names with the longest bearish Seeking Alpha Quant Ratings (Sell/Strong Sell).

Never miss news about GeneDx

Track GeneDx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

GeneDx competitors & trending companies

Browse news for competitors to GeneDx and other trending companies.